Summary & Overview
HCPCS J9063: Mirvetuximab Soravtansine-Gynx Injection, 1 mg
HCPCS Level II code J9063 denotes the injectable oncology agent mirvetuximab soravtansine-gynx, billed per 1 mg. As a specialized antibody-drug conjugate used in cancer care, this code captures high-cost drug administration that affects infusion workflows, payer coverage policies, and hospital outpatient billing. Nationally, accurate use of J9063 is important for claims processing, reimbursement tracking, and clinical cost management for oncology practices and health systems.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, typical site-of-service billing considerations, and common clinical contexts for use. Readers will find benchmarks for utilization and reimbursement structures, summaries of relevant policy updates affecting drug coding and billing, and clinical context describing how the product is administered and coded on the claim. The analysis clarifies where data is available and notes areas with limited publicly available information.
This summary provides clinicians, coders, and revenue leaders a concise reference for the code’s clinical purpose, expected billing setting, and the payer landscape relevant to mirvetuximab soravtansine-gynx.
Billing Code Overview
HCPCS Level II code J9063 represents the drug product mirvetuximab soravtansine-gynx, billed per 1 mg of the medication. This HCPCS code is used for administration of a targeted antibody-drug conjugate indicated in oncology treatment.
Service type: Drug administration / infusion therapy
Typical site of service: Outpatient hospital infusion center or oncology clinic infusion unit
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with recurrent or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma considered appropriate for targeted antibody-drug conjugate therapy. The patient presents to an outpatient oncology infusion center for intravenous administration of J9063 (mirvetuximab soravtansine-gynx). Prior to infusion, the oncology team confirms histology, prior treatment history, HER2/FRα expression if available, baseline labs (CBC, CMP), and vital signs. The infusion nurse verifies patient identity, checks chemotherapy orders, obtains weight for dose calculation, and prepares the calculated milligram dose using the single-agent vial strength. An oncology pharmacist compounds the dose under aseptic technique and performs independent verification. During infusion, the nurse monitors for infusion-related reactions, records medication administration and lot numbers, and manages premedication (eg, antiemetic, antipyretic, antihistamine, corticosteroid) per protocol. Post-infusion observation may be required for adverse event monitoring and documentation. Billing uses J9063 per milligram administered; JW/JZ modifiers may apply if partial doses or discarded drug occur. Typical site of service is an outpatient hospital-based or freestanding infusion center; administration is performed by oncology/hematology clinicians and certified infusion nurses.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |